NXC-401

NXC-401 is an investigational cell therapy candidate being developed by Nexcella, a subsidiary of Immix Biopharma, for the treatment of acute myeloid leukemia (AML). As of early 2024, the program is in the preclinical stage of development. While the specific molecular target of NXC-401 has not been publicly disclosed, it is part of Nexcella's pipeline of chimeric antigen receptor (CAR) T-cell therapies designed to address hematologic malignancies. The therapy aims to leverage engineered immune cells to specifically identify and eliminate AML blasts, potentially offering a new treatment modality for patients with this aggressive form of leukemia.